# EDGAR Filing Document

**Accession Number:** 0001971532
**File Stem:** 0001493152-25-021712
**Filing Date:** 2025-11
**Character Count:** 7710
**Document Hash:** dcd2be1de2c383560db62951e211c3a7
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-25-021712.hdr.sgml**: 20251112

**ACCESSION NUMBER**: 0001493152-25-021712

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20251112

**ITEM INFORMATION**: Other Events

**FILED AS OF DATE**: 20251112

**DATE AS OF CHANGE**: 20251112

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Telomir Pharmaceuticals, Inc.
- **CENTRAL INDEX KEY:** 0001971532
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 872606031
- **STATE OF INCORPORATION:** FL
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41952
- **FILM NUMBER:** 251468643

**BUSINESS ADDRESS:**
- **STREET 1:** 100 SE 2ND ST
- **STREET 2:** SUITE 2000 #1009
- **CITY:** MIAMI
- **STATE:** FL
- **ZIP:** 33131
- **BUSINESS PHONE:** 786-396-6723

**MAIL ADDRESS:**
- **STREET 1:** 100 SE 2ND ST
- **STREET 2:** SUITE 2000 #1009
- **CITY:** MIAMI
- **STATE:** FL
- **ZIP:** 33131

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the**

**Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): November 12, 2025**

**TELOMIR PHARMACEUTICALS, INC.**

**(Exact Name of Registrant as Specified in its Charter)**

---

| | | |
|:---|:---|:---|
| **Florida** | **001-41952** | **87-2606031** |
| **(State or Other Jurisdiction**<br> **of Incorporation)** | **(Commission** <br> **File Number)** | **(IRS Employer**<br> **Identification No.)** |

---

**100 SE 2nd St, Suite 2000, #1009**

**Miami, Florida 33131**

**(Address of Principal Executive Offices)**

**Registrant's telephone number, including area code: (786) 396-6723**

**Not Applicable**

**(Former Name or Former Address, if Changed Since Last Report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

<u>Title of each class</u> <u>Trading Symbol</u> <u>Name of each exchange on which registered</u> <br> Common Stock, no par value TELO The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 8.01 Other Events**

**Telomir Pharmaceuticals Reports That Telomir-1 Outperforms FDA-Approved Gold-Standard Iron Chelator Deferoxamine (DFO) in Reducing Intracellular Iron in a Human Cell Line**

 

*New live-cell imaging data show that Telomir-1 markedly lowers intracellular iron levels at submicromolar concentrations in human keratinocytes, demonstrating potent cell penetration and iron-modulating activity—key to its broader epigenetic mechanism of action.*

**Telomir Pharmaceuticals, Inc. (NASDAQ: TELO)** ("Telomir" or the "Company") reports new preclinical data demonstrating that its lead investigational compound **Telomir-1** produced a strong, dose-dependent reduction of intracellular iron in human keratinocyte (HaCaT) cells, **significantly exceeding** the effect observed with the FDA-approved iron chelator **Deferoxamine (DFO)**.

![](form8-k_001.jpg)

![](form8-k_002.jpg)

These results extend the Company's research into the relationship between metal-ion imbalance, oxidative stress, and epigenetic enzyme regulation.

**Study Overview**

The evaluation utilized **FerroOrange**, a fluorescent probe that selectively detects ferrous iron (Fe²⁺) in living cells. HaCaT cells were incubated with Telomir-1 or DFO at several time points. After three, six and sixteen hours, fluorescence microscopy showed substantially lower intracellular iron signal intensity in Telomir-1–treated cells at various concentrations, indicating greater cellular penetration and iron-modulating activity relative to DFO at the same concentrations.

**Scientific Context and Importance of the Findings**

Iron plays a vital role in human biology. It enables oxygen transport, mitochondrial energy generation, and DNA synthesis—processes essential for growth and cellular development. In early life, iron is beneficial and tightly regulated by proteins such as **ferritin**, **transferrin**, and **ceruloplasmin** that maintain balance between storage, transport, and utilization.

With aging, however, these control systems become less efficient. Reactive forms of iron can accumulate within cells, participating in chemical reactions that generate **reactive oxygen species (ROS)** capable of damaging DNA, proteins, and membranes. This imbalance contributes to oxidative stress, mitochondrial dysfunction, and genomic instability—factors increasingly associated with **accelerated aging**, **neurodegenerative, metabolic, cardiovascular, and oncologic diseases**.

Cancer biology further highlights the dual nature of iron. Many tumors depend on iron for rapid proliferation, using it to drive DNA replication, sustained proliferation and energy production. Yet excessive intracellular iron also amplifies oxidative and methylation stress, disrupting normal gene regulation and potentially promoting disease progression.

Understanding how to safely modulate intracellular iron levels is therefore an important area of pre-clinical research. The ability of Telomir-1 to enter cells and influence iron balance at low concentrations provides a basis for continued investigation into metal-ion homeostasis and its link to cellular health and epigenetic control.

**Key Observations**

● **Telomir-1** reduced intracellular Fe²⁺ levels in a time- and dose-dependent manner at low-micromolar concentrations.

● **Deferoxamine (DFO)**, while FDA-approved, exhibited limited intracellular activity under equivalent conditions.

● **Telomir-1** has also been formulated with zinc (**Telomir-Zn**) to enable a controlled intracellular exchange of metal ions—binding excess reactive metals such as iron and copper while contributing zinc, a cofactor for enzymes involved in antioxidant defense and DNA stability.

These data support the Company's ongoing pre-clinical research focused on **metal-ion balance, oxidative stress, and epigenetic enzyme dynamics** in aging and degenerative disease.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **TELOMIR PHARMACEUTICALS, INC.** | **TELOMIR PHARMACEUTICALS, INC.** |
| Dated: November 12, 2025 | By: | */s/ Erez Aminov&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;* |
|  | Name: | Erez Aminov |
|  | Title: | Chief Executive Officer |

---